Tekla Life Sciences Investors Aktie News

I maintain my buy rating on HQL due to its attractive 14% yield, discounted valuation, and long-term healthcare growth outlook. Despite recent NAV declines and inconsistent income, HQL's performance is tied to macro conditions, not internal flaws, and should improve as the sector rebounds. HQL's diversified biotech-heavy portfolio, lack of leverage, and simple strategy offer stability and upsid...

My definition of a high yield is any yield at least twice the level of the S&P 500's yield. The threshold is currently around 2.56%.

For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs wi...

HQL: Attractive Valuation, Aligned To Benefit From Aging Gen X

For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid tr...

Closed-end funds offer unique advantages, like buying at discounts and leveraging with institutionally priced debt, making them ideal income-generating vehicles. Cash distributions are key contributors to total return, but it is essential to be sure they are actually covered by fund earnings. Some investors overly prioritize distribution yields, neglecting the importance of considering total re...